Dr. Feuerstadt is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2200 Whitney Ave
Suite 360
Hamden, CT 06518Phone+1 203-281-4463Fax+1 203-287-2930
Education & Training
- Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Gastroenterology, 2007 - 2010
- New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2004 - 2007
- Weill Cornell MedicineClass of 2004
Certifications & Licensure
- NY State Medical License 2006 - 2027
- CT State Medical License 2010 - 2025
- FL State Medical License 2014 - 2016
- American Board of Internal Medicine Gastroenterology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Stool Sample Collection Protocol for Development of Screening Test for Colorectal Cancer and Other Digestive Tract Cancers Start of enrollment: 2014 Oct 01
Publications & Presentations
PubMed
- The 3 Ds: Depression, Dysbiosis, and Clostridiodes difficile.Antoine Boustany, Paul Feuerstadt, Glenn Tillotson
Advances in Therapy. 2024-11-01 - Endoscopic diagnosis and management of adult inflammatory bowel disease: a consensus document from the American Society for Gastrointestinal Endoscopy IBD Endoscopy Co..., Bo Shen, Maria T Abreu, Erica R Cohen, Francis A Farraye
Gastrointestinal Endoscopy. 2024-10-18 - 1 citationsSafety and Tolerability of CP101, a Full-Spectrum, Oral Microbiome Therapeutic for the Prevention of Recurrent Clostridioides difficile Infection: A Phase 2 Randomized...Jessica R Allegretti, Colleen R Kelly, Thomas Louie, Monika Fischer, Susy Hota
Gastroenterology. 2024-10-02
Authored Content
- C. Difficile Infection at DDW 2023May 2023
Press Mentions
- New AGA Podcast Series Explores the Latest in C. DifficileOctober 12th, 2023
- VIDEO: Low Risk for Congestive Heart Failure Exacerbation with Zinplava for C. DifficileMay 15th, 2023
- Four Analyses of Data for REBYOTA™ (Fecal Microbiota, Live – Jslm), the First FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrent C. Difficile Infection, Presented at DDW 2023May 8th, 2023
- Join now to see all
Professional Memberships
- Fellow
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: